BindingDB logo
myBDB logout

14 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
23773153 33 Targeting gain of function and resistance mutations in Abl and KIT by hybrid compound design.EBI Technical University of Dortmund
22621397 39 Irreversible protein kinase inhibitors: balancing the benefits and risks.EBI Covalution Pharma BV
17850214 99 The selectivity of protein kinase inhibitors: a further update.EBI University of Dundee
11277536 130 7-Pyrrolidinyl- and 7-piperidinyl-5-aryl-pyrrolo[2,3-d]pyrimidines--potent inhibitors of the tyrosine kinase c-Src.EBI Novartis Pharma Research
11277535 80 7-Alkyl- and 7-cycloalkyl-5-aryl-pyrrolo[2,3-d]pyrimidines--potent inhibitors of the tyrosine kinase c-Src.EBI Novartis Pharma Research
10866395 33 SAR of 4-hydroxypiperidine and hydroxyalkyl substituted heterocycles as novel p38 map kinase inhibitors.EBI Novartis Pharma AG
10853665 104 Substituted 5,7-diphenyl-pyrrolo[2,3d]pyrimidines: potent inhibitors of the tyrosine kinase c-Src.EBI Novartis Pharma AG
9599227 57 Development of a binding model to protein tyrosine kinases for substituted pyrido[2,3-d]pyrimidine inhibitors.EBI Warner-Lambert Company
12921854 130 Receptor affinities of dopamine D1 receptor-selective novel phenylbenzazepines.BDB Harvard University
10340630 3 Venlafaxine: discrepancy between in vivo 5-HT and NE reuptake blockade and affinity for reuptake sites.BDB McGill University
18849971 56 Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases.BDB University of California, San Francisco